Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three manufacturers of insulin, expanding low-cost access to the diabetes drug. Novo Nordisk agreed to cap insulin prices for the next five years so that Minnesotans won’t have to pay any more than $35 for monthly prescriptions.

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a month.

Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three major drug manufacturers.

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

Novo Nordisk has agreed to a legal settlement capping insulin prices, following Minnesota's attorney general's accusations of price gouging. The settlement mandates a price cap of $35 per monthly prescription and provides free insulin to needy Minnesotans.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years. State Attorney General Keith Ellison says that’s the result of a settlement announced Monday with Novo Nordisk.

Novo Nordisk has agreed to cap insulin prices at $35, settling a lawsuit from Minnesota's Attorney General over allegations of inflated drug prices. The settlement, lasting five years, also provides free insulin to the neediest.